Amarin (AMRN) Dips Following FDA Orange Book Update

January 18, 2013 2:35 PM EST Send to a Friend
Amarin Corp Plc (NASDAQ: AMRN) shares are pressured following an update to the FDA's Orange Book.

The Book had Amarin's Vascepa with "no unexpired exclusivity for this product," though no NCE decision was made.

Shares are down 7.5 percent Friday afternoon.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment